---

CCR5 antagonist: Promising agents in HIV treatment

---

Review Article

Author Details : Amit G. Nerkar*, Guno. S. Chakraborthy

Volume : 5, Issue : 4, Year : 2023

Article Page : 123-129

https://doi.org/10.18231/j.ctppc.2023.027

Suggest article by email

Get Permission

---

Abstract

HIV enters the bloodstream via binding to receptors on the surface of host cells. The CD4+ cell is a kind of white blood cell. Viral access to It all starts with the CD4+ cell. R5 HIV-1 Virus Attachment gp120 (glycoprotein 120) to The CD4+ T-cell receptor (CD4+ TCR) is a type of T-cell receptor that gives rise to a conformational a modification in gp120 that enables it to connect to CCR5, causing it to activate gp41 (glycoprotein 41) mediates the viral envelope is fused with membrane of the cell and the nucleocapsid makes its way into the host a cell. CCR5 is a kind of co-receptor by inhibiting CCR5 cell surface, antagonists prevent HIV-1 from entering and infecting immune cells receptor. CCR5 antagonists are small molecules that attach to a hydrophobic pocket produced by CCR5. The CCR5 receptor's trans membrane helices They're thought to interact with the receptor in the brain. The review gives a brief description of currently used CCR5 antagonists.

Keywords: CCR5, HIV, Nucleocapsid, Pharmacophore, Drug design, Binding, Antagonist

How to cite : Nerkar A G, Chakraborthy G S, CCR5 antagonist: Promising agents in HIV treatment. Curr Trends Pharm Pharm Chem 2023;5(4):123-129

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.